Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma

Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma

Author Andrade, Valeria C. C. Google Scholar
Vettore, Andre L. Autor UNIFESP Google Scholar
Regis Silva, Maria Regina Autor UNIFESP Google Scholar
Felix, Roberta S. Google Scholar
Almeida, Manuella S. S. Google Scholar
Carvalho, Fabricio de Google Scholar
Zago, Marco Antonio Google Scholar
Caballero, Otavia L. Google Scholar
Simpson, Andrew J. Google Scholar
Colleoni, Gisele W. B. Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Universidade de São Paulo (USP)
Ludwig Inst Canc Res
Abstract Objective. This study aims to analyze the expression of cancer testis antigen 45 (CT45) in normal tissues and in plasma cell disorders and to identify possible associations with clinical data and prognosis in multiple myeloma (MM) patients.Materials and Methods. Expression of CT45 was studied in 20 normal tissues (testis, placenta, skeletal muscle, bladder, lung, spleen, heart, brain and fetal brain, thymus, uterus, stomach, mammary gland, pancreas, prostate, small intestine, kidney, adrenal gland, spinal cord, colon, and one pool of 10 normal bone marrow samples) and bone marrow aspirates from 3 monoclonal gammopathies of undetermined significance, 5 solitary plasmacytomas, 61 newly diagnosed MM patients and MM cell line U266 by reverse transcriptase polymerase chain reaction.Results. CT45 was positive in 3 of 20 (15%) normal tissues tested: lung, brain (both fetal and adult), and spinal cord. Among monoclonal gammopathies, CT45 was positive in 2 of 5 (40%) solitary plasmacytomas bone marrow aspirates, 10 of 61 (16%) MM bone marrow aspirates, and in the U266 MM cell line.Conclusions. We did not find associations between bone marrow histology and CT45 expression. However, we demonstrated for the first time that positive expression of CT45 was associated with poor prognostic (international Staging System) and poor outcomes in MM patients, meaning that CT45-positive cases presented seven times more chance of worse evolution than the negative ones. (C) 2009 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.
Language English
Sponsor Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Grant number FAPESP: 04/13213-3
FAPESP: 04/12855-1
Date 2009-04-01
Published in Experimental Hematology. New York: Elsevier B.V., v. 37, n. 4, p. 446-449, 2009.
ISSN 0301-472X (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 446-449
Access rights Closed access
Type Article
Web of Science ID WOS:000264735300003

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account